171 related articles for article (PubMed ID: 25012524)
1. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
van Soest RJ; de Wit R; van Weerden WM
Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
[No Abstract] [Full Text] [Related]
2. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
Tombal B
Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
[No Abstract] [Full Text] [Related]
3. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
Shiota M; Yokomizo A
Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
[No Abstract] [Full Text] [Related]
4. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
[No Abstract] [Full Text] [Related]
5. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
Arslan C
World J Urol; 2017 Mar; 35(3):479-480. PubMed ID: 27417948
[No Abstract] [Full Text] [Related]
6. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
Dhawan M; Ryan CJ
Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
[TBL] [Abstract][Full Text] [Related]
7. Re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Lu K
Eur Urol; 2015 Dec; 68(6):e129-31. PubMed ID: 26318711
[No Abstract] [Full Text] [Related]
8. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.
O'Cathail M; Sundar S
Eur Urol; 2015 Jun; 67(6):e113-e114. PubMed ID: 25534667
[No Abstract] [Full Text] [Related]
9. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
Caffo O; Maines F; Veccia A
Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376
[No Abstract] [Full Text] [Related]
10. Metastasis: Resistance fighters.
Savage N
Nature; 2015 Dec; 528(7582):S128-9. PubMed ID: 26672785
[No Abstract] [Full Text] [Related]
11. Secondary hormone therapy for castration-resistant prostate cancer.
Taplin ME
Oncology (Williston Park); 2013 May; 27(5):371-2. PubMed ID: 25184257
[No Abstract] [Full Text] [Related]
12. Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
de Wit R; Tombal B; Freedland S
Eur Urol; 2021 Feb; 79(2):170-172. PubMed ID: 33218827
[TBL] [Abstract][Full Text] [Related]
13. Towards random sequencing or precision medicine in castration-resistant prostate cancer?
Loriot Y; Fizazi K
Eur Urol; 2014 Jan; 65(1):37-8. PubMed ID: 24075577
[No Abstract] [Full Text] [Related]
14. Impact of taxanes on androgen receptor signaling.
Bai S; Zhang BY; Dong Y
Asian J Androl; 2019; 21(3):249-252. PubMed ID: 29900882
[TBL] [Abstract][Full Text] [Related]
15. [2017 ASCO: Complete androgen blockade strikes back].
Penel N
Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
[No Abstract] [Full Text] [Related]
16. Re: Börje Ljungberg, Laurence Albiges, Yasmin Abu-Ghanem, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.006.
Wei Y; Zhang R; Lin L
Eur Urol; 2022 Sep; 82(3):e88. PubMed ID: 35750581
[No Abstract] [Full Text] [Related]
17. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
van Soest RJ; de Wit R
Eur Urol; 2017 Jan; 71(1):e9-e10. PubMed ID: 27746063
[No Abstract] [Full Text] [Related]
18. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
Roviello G; Generali D; Petrioli R
Eur Urol; 2017 Feb; 71(2):e55. PubMed ID: 27543166
[No Abstract] [Full Text] [Related]
19. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
Fenner A
Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
[No Abstract] [Full Text] [Related]
20. Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup
Ann Acad Med Singap; 2015 Oct; 44(10):397-405. PubMed ID: 26763057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
